Netscientific PLC
LSE:NSCI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (0), the stock would be worth GBX-0.58 (101% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -4.2 | GBX53.5 |
0%
|
| Industry Average | 0 | GBX-0.58 |
-101%
|
| Country Average | 0 | GBX-0.38 |
-101%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
GBX16.2m
|
/ |
Jan 2024
£-3.9m
|
= |
|
|
GBX16.2m
|
/ |
Dec 2024
£-3.3m
|
= |
|
|
GBX16.2m
|
/ |
Dec 2025
£-646.4k
|
= |
|
|
GBX16.2m
|
/ |
Dec 2026
£555.5k
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Netscientific PLC
LSE:NSCI
|
14.6m GBP | -4.2 | -5.5 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 55.9 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 18.8 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 23.9 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 18.8 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 25.3 | 31.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 15.1 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 27.2 | 45.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 33.3 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 16.6 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 16.8 | 21.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0.1 |
| Max | 1 015 |
Other Multiples
Netscientific PLC
Glance View
NetScientific Plc is a healthcare medical technology company, which engages in sourcing, funding, and commercializing technologies that improve the health and well-being of people with chronic diseases. Its portfolio consists of a combination of direct investments and capital under advisory. The company has developed a customized investment and realization strategy for its portfolio companies through management, incubation, advisory services and fund-raising support. The company facilitates the companies it works with, to access the type of funding, management support and resources specific to their sector, stage of development and available opportunities. The firm's subsidiaries include EMV Capital Limited, Glycotest, Inc. and ProAxsis Limited, among others.
